- Headquarters
- Seongnam
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Website
- d5tx.com
- Last Round
- Venture RoundSep 2023
- Rounds
- 1
About
D5 Therapeutics is a South Korean biotechnology company founded in 2021, focused on discovering novel oncology targets and developing innovative cancer medicines using a synthetic lethality approach. The company leverages a data-driven platform technology to identify drug candidates including DT01 (cisplatin-resistant cancer), DT03 (HR-deficient cancer), DT04 (PARP inhibitor-resistant cancer), and DT05 (breast cancer). Its approach exploits genetic vulnerabilities in cancer cells to develop targeted therapies with improved selectivity and reduced toxicity compared to conventional treatments. D5 Therapeutics is headquartered in Seongnam-si, South Korea and is backed by investors including Timefolio Capital.
Summary
D5 Therapeutics is a Biotech company based in Seongnam, South Korea, founded in 2021. Its most recent funding was a Venture Round round in Sep 2023. Investors include Hana Ventures.
Funding History
Sep 2023
Investors
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Novel bicyclic peptides and drug conjugates for cancer
Clinical-stage biopharmaceutical company founded in 2015 developing best-in-class cancer therapeu...
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/d5-therapeutics"><img src="https://indexed.vc/api/badge/company/d5-therapeutics" alt="D5 Therapeutics on Indexed.vc" width="260" height="76" /></a>